Home > Clinical Trials
Check All Search

Saved trials

SUSPENDED
NCT04616560
Trastuzumab Deruxtecan for the Treatment of HER2+ Newly Diagnosed or Recurrent Osteosarcoma
77 Enrollment(s)
28 Study location(s)
INTERVENTIONAL (PHASE2)
Osteosarcoma


Recurrent Osteosarcoma
RECRUITING
NCT04585958
Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer
55 Enrollment(s)
5 Study location(s)
INTERVENTIONAL (PHASE1)
Metastatic Malignant Solid Neoplasm


Platinum-Resistant Ovarian High Grade Serous Adenocarcinoma


Unresectable Malignant Solid Neoplasm
RECRUITING
NCT07198724
ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer
65 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE1|||PHASE2)
Metastatic Breast Cancer


HER2 Low Breast Carcinoma


HER2-negative Breast Cancer


Breast Cancer


Breast Cancer Female
RECRUITING
NCT06764875
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
840 Enrollment(s)
286 Study location(s)
INTERVENTIONAL (PHASE3)
HER2-positive Gastric Cancer


Gastroesophageal Junction Adenocarcinoma
ACTIVE_NOT_RECRUITING
NCT04482309
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
477 Enrollment(s)
89 Study location(s)
INTERVENTIONAL (PHASE2)
Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer


Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer
RECRUITING
NCT06989112
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
600 Enrollment(s)
249 Study location(s)
INTERVENTIONAL (PHASE3)
Endometrial Cancer
RECRUITING
NCT05950945
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
250 Enrollment(s)
86 Study location(s)
INTERVENTIONAL (PHASE3)
Breast Cancer
ACTIVE_NOT_RECRUITING
NCT05034887
Phase 2 Study of Trastuzumab Deruxtecan in the Neoadjuvant Treatment, or Trastuzumab Deruxtecan Plus Capecitabine Plus Durvalumab(MEDI4736) in the Preoperative and Postoperative Adjuvant Treatment for Patients With HER2 Positive Gastric and Gastroesophageal Junction Adenocarcinoma
64 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE2)
Gastric Adenocarcinoma


Gastroesophageal Junction Adenocarcinoma